The Gross Law Firm issues the following notice to shareholders of Lululemon Athletica Inc. (NASDAQ: LULU). https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg Shareholders who purchased shares of LULU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/lululemon-athletica-inc-loss-submission-form/?id=104036&from=4 CLASS […]

The Gross Law Firm issues the following notice to shareholders ofDXC Technology Company (NYSE: DXC). https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg Shareholders who purchased shares of DXC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: DXC Technology

The Gross Law Firm issues the following notice to shareholders of Starbucks Corporation (NASDAQ: SBUX). https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg Shareholders who purchased shares of SBUX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/starbucks-loss-submission-form/?id=104034&from=4 CLASS PERIOD:

The Gross Law Firm issues the following notice to shareholders of Indivior PLC (NASDAQ: INDV). https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg Shareholders who purchased shares of INDV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/indivior-loss-submission-form/?id=104033&from=4 CLASS PERIOD:

The Gross Law Firm issues the following notice to shareholders of NANO Nuclear Energy Inc. (NASDAQ: NNE). https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg Shareholders who purchased shares of NNE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/nano-nuclear-energy-inc-loss-submission-form/?id=104032&from=4

The Gross Law Firm issues the following notice to shareholders ofSymbotic Inc. (NASDAQ: SYM). https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg Shareholders who purchased shares of SYM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: Symbotic Loss Submission

The Gross Law Firm issues the following notice to shareholders of Stellantis N.V. (NYSE: STLA). https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg Shareholders who purchased shares of STLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/stellantis-loss-submission-form/?id=104030&from=4 CLASS PERIOD:

The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM). https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: DexCom, Inc.

The Gross Law Firm issues the following notice to shareholders of Orthofix Medical Inc. (NASDAQ: OFIX). https://mma.prnewswire.com/media/2280333/The_Gross_Law_Firm_Logo.jpg Shareholders who purchased shares of OFIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: Orthofix

— XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. — XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug application (NDA) for XPOVIO® in Indonesia with approval expected in the second half of 2024. — XPOVIO® has been approved for health